Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments ...

SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...

SWTX stock opened at $57.43 on Wednesday. The company has a market cap of $4.27 billion, a price-to-earnings ratio of -14.80 and a beta of 0.81. SpringWorks Therapeutics has a twelve month low of ...

Daniel Pichl, the Chief People Officer of $SWTX, sold 13,750 shares of the company on 02-10-2025 for an estimated $728,997. We received data on the trade from a ...

TD Cowen raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $66 from $63 and keeps a Buy rating on the shares. The firm says ...

BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...